MPLT Stock Forecast & Price Target

MapLight Therapeutics is viewed favorably because ML-007C-MA has shown clinically meaningful differentiation in schizophrenia, including a PANSS improvement of 4.5 points at week 5, a Cohen’s d of 0.37, and a robust cognitive signal with an effect size of 0.51 in impaired participants. Its safety and tolerability profile, including no urinary retention and central receptor activity paired with peripheral side-effect mitigation, supports the argument that it may be better suited for older patients and the larger Alzheimer’s disease psychosis opportunity. The company also strengthened its balance sheet with a $150M PIPE financing, and despite dilution concerns, the advanced VISTA program and expected 2H27 readout keep the long-term pipeline compelling.

MapLight Therapeutics is a high-risk clinical-stage company whose outlook is weakened by dependence on a single lead asset in difficult CNS markets, where trial failures, regulatory setbacks, and commercialization hurdles could materially impair value. Although ML-007C-MA showed meaningful efficacy in the ZEPHYR trial, the once-daily regimen missed its primary endpoint and the schizophrenia safety profile appears to worsen, eroding the differentiation needed against Cobenfy and limiting market penetration. The case is further pressured by reduced approval odds of 50% in schizophrenia and 30% in ADP, a delayed likely launch year of 2031 and 2032, and meaningful dilution risk that could offset a ~$900M enterprise value and ~$1.3B total firm value.